1don MSN
TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company’s Position to be a Leader
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best AI stocks to buy according to analysts. On December 8, TD Cowen reaffirmed ...
Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...
The FDA has played an active role in US Health Secretary Robert F. Kennedy Jr.’s agenda to scrutinize vaccines, even if the ...
The "Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course (Feb 11th - Feb 12th, 2026)" training has been added to ResearchAndMarkets.com's offering.
The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a ...
Botanic Tonics’ supplement drinks have taken convenience stores by storm—even as the company has battled allegations of ...
MedPage Today on MSNOpinion
'I Don't Know How Many Died': What We Heard This Year
In place of our usual "What We Heard This Week" feature, and as part of our year-end wrap-ups, we've selected some of the ...
Today, China ranks second only to the United States in the number of new drugs under development, with its pipeline ...
4don MSN
Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...
A recent randomised controlled trial showed that proton pump inhibitors (PPIs), compared with histamine-2 receptor antagonists (H2RAs), induce greater gut microbiome alterations and oral-to-gut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback